Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...

New research from the Florida State University Department of Chemistry and Biochemistry shows that a particular type of monoclonal antibody known as NISTmAb retains its structure even if the sugar ...

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help ...

Tiziana Life Sciences announces discovery of new immune biomarkers in multiple sclerosis patients treated with nasal foralumab: New York Friday, January 24, 2025, 17:00 Hrs [IST] ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Accordingwill be interviewing current and former staffers about their experience on the set of the talk show, hosted by Ellen DeGeneres.

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody ... to the discovery, development and commercialization of innovative therapeutics. The company has established a ...

A data scientist standing in front of a large monitor presenting a drug discovery analysis ... when it collaborated with ...